Efficacy and safety of on-demand dapoxetine combined with phosphodiesterase-5 inhibitor compared to monotherapy dapoxetine as a treatment of premature ejaculation without erectile dysfunction: a systematic review and meta-analysis
Open Access
- 30 September 2025
- journal article
- research article
- Published by PAGEPress Publications in Archivio Italiano di Urologia e Andrologia
- Vol. 97 (3) , 14117
Abstract
Background: Premature ejaculation (PE) affects about 30% of the male population. The European Association of Urology (EAU) guidelines state that monotherapy dapoxetine on-demand has been successfully used to treat PE throughout Europe. Several studies have stated that when dapoxetine and phosphodiesterase-5 inhibitor (PDE-5i) are used combined, sexual enjoyment and intravaginal ejaculation latency time (IELT) are increased more than when dapoxetine is taken alone. However, further investigation is needed to determine whether PDE-5i and dapoxetine can be safely consumed together.Methods: This study was conducted using 5 randomized controlled trials (RCTs), which systematically extracted from online databases, namely Science Direct, PubMed, Google Schoolar and Cochrane Library. Included studies were assessed using Cochrane Risk of Bias (RoB) 2.0 for RCTs. The data analysis was performed using RevMan software 5.1 of the Cochrane Collaboration.Results: Five RCTs with a total of 498 potent men with PE from the period 2013-2024 showed pooled mean difference of dapoxetine + PDE-5i was found significantly associated with higher post-treatment IELT scores compared to monotherapy dapoxetine (MD 1.08; 95% CI 0.34-1.83; p=0.004; I2 = 95%; 4 RCTs). The pooled mean difference of dapoxetine + PDE-5i also showed statistically significant association with higher post-treatment sexual satisfaction scale (SSS) scores compared to monotherapy dapoxetine (MD 0.76; 95% CI 0.49-1.04; p<0.00001; I2 = 68%; 2 RCTs). Among 10 adverse effects (headacahe, flushing, nausea, dizziness, fatigue, nasal congestion, palpitation, vomitting, sleep disturbance, and constipation), the use of combination therapy is presenting significantly higher incidence of headache, flushing, nasal congestion compared to monotherapy dapoxetine (RR 3.00; 95% CI: 1.91-4.71; p<0.00001; I2: 0%; 5 RCTs), (RR 15.78; 95% CI: 5.48-45.45; p<0.00001; I2: 24%; 5 RCTs), (RR 9.00; 95% CI: 1.17-69.01; p=0.03; I2: 0%; 2 RCTs), respectively.Conclusions: This study demonstrates that the combination of dapoxetine and PDE-5i significantly improves post-treatment scores of IELT and sexual satisfaction compared to dapoxetine monotherapy. Despite an increased risk of certain side effects, the overall tolerability of the combination therapy remains favorable.Keywords
This publication has 15 references indexed in Scilit:
- Prospective comparison of tadalafil 5 mg, dapoxetine 30 mg, and the combination of both in the treatment of premature ejaculationArab Journal of Urology, 2023
- Comparison of the clinical efficacy and safety of the on-demand use of paroxetine, dapoxetine, sildenafil and combined dapoxetine with sildenafil in treatment of patients with premature ejaculation: A randomised placebo-controlled clinical trialAndrologia, 2017
- Current Pharmacological Management of Premature Ejaculation: A Systematic Review and Meta-analysisEuropean Urology, 2016
- Paternal dapoxetine administration induced deterioration in reproductive performance, fetal outcome, sexual behavior and biochemistry of male ratsInternational Journal Of Impotence Research, 2015
- Assessing satisfaction in men with premature ejaculation after dapoxetine treatment in real-world practiceInternational Journal Of Clinical Practice, 2015
- Combination therapy with selective serotonin reuptake inhibitors and phosphodiesterase-5 inhibitors in the treatment of premature ejaculationAndrologia, 2014
- Comparison Between On-Demand Dosing of Dapoxetine Alone and Dapoxetine Plus Mirodenafil in Patients with Lifelong Premature Ejaculation: Prospective, Randomized, Double-Blind, Placebo-Controlled, Multicenter StudyThe Journal of Sexual Medicine, 2013
- Is there a role for phosphodiesterase type-5 inhibitors in the treatment of premature ejaculation?International Journal Of Impotence Research, 2011
- Tadalafil and Fluoxetine in Premature Ejaculation: Prospective, Randomized, Double-Blind, Placebo-Controlled StudyUrologia Internationalis, 2008
- Dapoxetine, a novel treatment for premature ejaculation, does not have pharmacokinetic interactions with phosphodiesterase-5 inhibitorsInternational Journal Of Impotence Research, 2005